



## SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR

DUBLIN, Calif., April 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- SuperGen Inc. (Nasdaq: SUPG) announced today that it will have multiple presentations at the American Association for Cancer Research Annual Meeting on April 14-18 in Los Angeles. These presentations will focus on data concerning many of SuperGen's current oncology programs including its lead tyrosine kinase inhibitor compound, MP470 and its ability to block Rad51, a key protein target involved in cancer cell drug resistance. Presentations will take place in the exhibit hall of the Los Angeles Convention Center.

The schedule of SuperGen's presentations is:

Date	Time (PDT)	Title	Poster Number/Section
Sunday, April 15	1 p.m. - 5 p.m.	Hydrochloride salt of MP470, a potent suppressor of Rad51, improves bioavailability and tolerability	#1540  Poster Section 31
Monday, April 16	8 a.m. - 12 p.m.	Discovery and characterization of a series of Axl kinase inhibitors using the CLIMB(TM) process	#2380  Poster Section 30
Monday, April 16	8 a.m. - 12 p.m.	Discovery and characterization of small molecule inhibitors for Jak2	#2387  Poster Section 30
Monday, April 16	8 a.m. - 12 p.m.	Zebrafish as a model mechanistic screen for small molecule inhibitors of DNMT1	#2229  Poster Section 23
Monday, April 16	1 p.m. - 5 p.m.	Discovery and development of MP529, a new effective and selective inhibitor of Aurora A kinase	#3261  Poster Section 29
Tuesday, April 17	8 a.m. - 12 p.m.	MP470, a potent suppressor of Rad51, improves response to platinum-based anticancer agents	#4028  Poster Section 29
Tuesday, April 17	10:40 a.m. - 10:55 a.m.	Novel DNA hypomethylating agents: non-	#4142  Minisymposium

	nucleoside compounds that do not incorporate into DNA selectively induce degradation of DNA methyltransferase I (DNMT1) in human cancer cells by the proteasomal pathway and re-express silenced tumor suppressor genes	Cancer Epigenetics  Room 304 A-C
Wed., April 18	8 a.m. - 12 p.m.	Dual inhibition of receptor tyrosine kinases of PDGFR and EGFR abolishes prostate cancer cell growth in culture and in a mouse xenograft model by complete dephosphorylation of PKB/Akt
		#5421  Poster Section 20

#### About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit <http://www.supergen.com>.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

#### Contacts:

SuperGen  
Timothy L. Enns  
S.V.P., Corporate Communications  
& Business Development  
(925) 560-0100 x111  
[tenns@supergen.com](mailto:tenns@supergen.com)

Noonan Russo  
Greg Geissman  
Director of Media Relations  
  
(619) 814-3510  
[greg.geissman@eurorscg.com](mailto:greg.geissman@eurorscg.com)

<http://www.supergen.com>

SOURCE SuperGen Inc.